Do you want to read an article? Please log in or register.
Patient Characteristics and Real-World Treatment Patterns Among Early Users of PCSK9 Inhibitors
Lipids
Related content
COMMENTED
Type 2 Diabetes
Comparing medication persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists in real-world setting
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Diabetes Res Clin Pract
Rea F, Ciardullo S, Savaré L, Perseghin G, Corrao G
doi: 10.1016/j.diabres.2021.109035
COMMENTED
Type 2 Diabetes
Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
★ 2
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Lancet Diabetes Endocrinol.
Heerspink HJL, Karasik A, Thuresson M, Melzer-Cohen C, Chodick G, Khunti K, Wilding JPH, Garcia Rodriguez LA, Cea-Soriano L, Kohsaka S, Nicolucci A, Lucisano G, Lin FJ, Wang CY, Wittbrodt E, Fenici P, Kosiborod M
doi: 10.1016/S2213-8587(19)30384-5.
Diabetes - GeneralType 2 Diabetes
Lower Risk of Heart Failure and Death in Patients Initiated on SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study
Circulation.
Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen M, Thuresson M, Arya N, Bodegård J, Hammar N, Fenici P; CVD-REAL Investigators and Study Group
doi: 10.1161/CIRCULATIONAHA.
COMMENTED
Diabetes - General
Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 35 Randomized Controlled Trials
J Am Heart Assoc.
Karatasakis A, Danek BA, Karacsonyi J, Rangan BV, Roesle MK, Knickelbine T, Miedema MD, Khalili H, Ahmad Z, Abdullah S, Banerjee S, Brilakis ES
doi: 10.1161/JAHA.117.006910.
Further Publications
Treatment patterns and persistence rates with anti-VEGF treatment for diabetic macular edema in the UK: a real-world study
Diabet Med
Peto T, Akerele T, Sagkriotis A, Zappacosta S, Clemens A, U Chakravarthy
doi: 10.1111/dme.14746
Glycemic Control
The Effect of 6 Months' Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings
Front Endocrinol (Lausanne)
Witek P, Bolanowski M, Szamotulska K, Wojciechowska-Luźniak A, Jawiarczyk-Przybyłowska A, Kałużny M
doi: 10.3389/fendo.2021.633944
COMMENTED
Diabetes - GeneralType 2 Diabetes
Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes
JAMA Intern Med.
Chang HY, Singh S, Mansour O, Baksh S, Alexander GC
doi: 10.1001/jamainternmed.
Diabetes - GeneralType 2 DiabetesGlycemic Control
Time to Treatment Intensification After Monotherapy Failure and Its Association With Subsequent Glycemic Control Among 93,515 Patients With Type 2 Diabetes
Diabetes Care.
Desai U, Kirson NY, Kim J, Khunti K, King S, Trieschman E, Hellstern M, Hunt PR, Mukherjee J
doi: 10.2337/dc17-0662.
Diabetes - GeneralType 2 Diabetes
Weight gain in insulin treated patients by BMI categories at treatment initiation: New evidence from real-world data in patients with type 2 diabetes
Diabetes Obes Metab.
Paul SK, Shaw J, Montvida O, Klein K
doi: 10.1111/dom.12761.